康华生物
(300841)
| 流通市值：80.12亿 | | | 总市值：87.39亿 |
| 流通股本：1.22亿 | | | 总股本：1.33亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 931,949,521.9 | 1,001,326,623.71 | 762,341,572.72 | 770,074,519.38 |
| 应收票据及应收账款 | 1,211,775,915.46 | 1,298,879,167.25 | 1,393,896,195.41 | 1,430,148,717.53 |
| 其中：应收票据 | - | - | 700,000 | - |
| 应收账款 | 1,211,775,915.46 | 1,298,879,167.25 | 1,393,196,195.41 | 1,430,148,717.53 |
| 预付款项 | 11,865,524.24 | 9,936,970.07 | 10,568,889.01 | 13,322,348.47 |
| 其他应收款合计 | 1,509,818.17 | 775,469.16 | 13,285,137.56 | 13,258,862.62 |
| 存货 | 188,083,939.24 | 176,882,114.2 | 180,436,269.87 | 193,763,461.09 |
| 其他流动资产 | 9,089,810.09 | 200,757.7 | - | - |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 2,354,274,529.1 | 2,488,001,102.09 | 2,360,528,064.57 | 2,420,567,909.09 |
| 非流动资产: | | | | |
| 长期股权投资 | 6,353,329.95 | 6,353,329.95 | 6,500,000 | 6,500,000 |
| 其他非流动金融资产 | 410,132,731.53 | 410,026,700 | 461,745,354.2 | 466,293,841.37 |
| 固定资产 | 938,121,029.44 | 955,905,539.03 | 840,217,214.48 | 825,965,040.68 |
| 在建工程 | 2,759,505.27 | 3,040,600 | 124,408,297.53 | 119,379,650.21 |
| 无形资产 | 16,502,701.01 | 17,513,971.83 | 15,829,180.83 | 15,776,156.94 |
| 长期待摊费用 | 151,028,972.98 | 142,520,407.62 | 137,019,441.7 | 117,415,454.47 |
| 递延所得税资产 | 2,365,900.05 | 2,073,188.56 | 525,073.85 | 1,247,742.53 |
| 其他非流动资产 | 2,128,931.72 | 2,147,434.89 | 3,994,313.5 | 6,561,941.9 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,529,393,101.95 | 1,539,581,171.88 | 1,590,238,876.09 | 1,559,139,828.1 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 3,883,667,631.05 | 4,027,582,273.97 | 3,950,766,940.66 | 3,979,707,737.19 |
| 流动负债: | | | | |
| 短期借款 | 161,323,081.2 | 186,888,656.44 | 216,432,123.41 | 176,401,929 |
| 应付票据及应付账款 | 7,854,097.24 | 5,903,281.65 | 6,151,719.05 | 6,218,911.5 |
| 其中：应付票据 | 937,615.11 | 937,615.11 | 937,615.11 | - |
| 应付账款 | 6,916,482.13 | 4,965,666.54 | 5,214,103.94 | 6,218,911.5 |
| 合同负债 | 988,011.65 | 1,000,749.51 | 105,605.83 | 207,372.82 |
| 应付职工薪酬 | 10,600,668.63 | 33,366,604.22 | 20,616,419.74 | 17,396,965.67 |
| 应交税费 | 3,114,284.9 | 11,366,004 | 11,775,775.78 | 22,474,380.21 |
| 其他应付款合计 | 222,226,527.98 | 327,813,468.03 | 230,947,075.66 | 306,556,812.89 |
| 应付股利 | - | 2,800,937.4 | - | - |
| 其他流动负债 | 29,640.35 | 30,022.49 | 3,168.17 | 6,221.18 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 406,136,311.95 | 566,368,786.34 | 486,031,887.64 | 529,262,593.27 |
| 非流动负债: | | | | |
| 预计负债 | 3,147,028.12 | 7,537,791.35 | 3,809,053.37 | 3,222,290.15 |
| 递延收益 | 6,167,000 | 6,167,000 | 6,167,000 | 6,182,456.4 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 9,314,028.12 | 13,704,791.35 | 9,976,053.37 | 9,404,746.55 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 415,450,340.07 | 580,073,577.69 | 496,007,941.01 | 538,667,339.82 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 132,946,899 | 132,946,899 | 134,650,449 | 134,650,449 |
| 资本公积 | 1,082,492,146.04 | 1,082,492,146.04 | 1,179,543,389.54 | 1,179,543,389.54 |
| 减:库存股 | 224,340,372.53 | 224,340,372.53 | 323,095,166.03 | 237,466,383.75 |
| 盈余公积 | 67,325,224.5 | 67,325,224.5 | 67,325,224.5 | 67,325,224.5 |
| 未分配利润 | 2,409,793,393.97 | 2,389,084,799.27 | 2,396,335,102.64 | 2,296,987,718.08 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 3,468,217,290.98 | 3,447,508,696.28 | 3,454,758,999.65 | 3,441,040,397.37 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 3,468,217,290.98 | 3,447,508,696.28 | 3,454,758,999.65 | 3,441,040,397.37 |
| 负债和股东权益合计 | 3,883,667,631.05 | 4,027,582,273.97 | 3,950,766,940.66 | 3,979,707,737.19 |
| 公告日期 | 2025-04-19 | 2025-04-19 | 2024-10-29 | 2024-08-17 |
| 审计意见(境内) | | 标准无保留意见 | | |